Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14-16 weeks: A randomized trial

Lynn Borgatta, Danielle Roncari, Sarita Sonalkar, Alice Mark, Melody Hou, Molly Finneseth, Olivera Vragovic

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Background: Cervical preparation is recommended before second-trimester abortion. We investigated the use of a pharmacologic method of preparation, mifepristone, as compared to osmotic dilators for surgical abortions at 14-16 weeks. Study Design: This was a randomized, parallel-group study with concealed allocation. Women were allocated to receive osmotic dilators or mifepristone 200 mg orally 24 h prior to abortion. The study population was 50 women seeking surgical abortion at 14-16 menstrual weeks in a hospital-based abortion service. The primary outcome was the length of time to perform the procedure; the study had 80% power to detect a difference of more than 3 min in procedure time. Secondary outcomes included cervical dilation, side effects and acceptability. Results: The mean abortion time for the osmotic dilator group was 8.00 min [95% confidence interval (CI) 6.75-11.47], and that for the mifepristone group was 9.87 min (95% CI 8.93-11.36). Side effects of pain were more common in the osmotic dilator group. Conclusion: Mifepristone did not increase the time for abortion by more than the prespecified margin (3 min). Women preferred mifepristone to osmotic dilators.

Original languageEnglish (US)
Pages (from-to)567-571
Number of pages5
JournalContraception
Volume86
Issue number5
DOIs
StatePublished - Nov 2012
Externally publishedYes

Keywords

  • Abortion
  • Cervical priming
  • Laminaria
  • Mifepristone
  • Osmotic dilators
  • Second trimester

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14-16 weeks: A randomized trial'. Together they form a unique fingerprint.

  • Cite this